Icon Plc (NASDAQ:ICLR) has earned an average recommendation of “Buy” from the twelve brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $156.14.
A number of research firms have recently commented on ICLR. BidaskClub lowered shares of Icon from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 23rd. Barclays reaffirmed a “hold” rating and set a $154.00 target price on shares of Icon in a research report on Wednesday, April 17th. Zacks Investment Research raised shares of Icon from a “hold” rating to a “buy” rating and set a $155.00 target price on the stock in a research report on Friday, May 17th. Mizuho boosted their target price on shares of Icon from $154.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Finally, ValuEngine lowered shares of Icon from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th.
A number of hedge funds have recently made changes to their positions in ICLR. Truehand Inc acquired a new stake in Icon during the fourth quarter worth $54,000. Ellis Investment Partners LLC acquired a new stake in Icon during the first quarter worth $59,000. NumerixS Investment Technologies Inc acquired a new stake in Icon during the fourth quarter worth $64,000. O Shaughnessy Asset Management LLC acquired a new stake in Icon during the fourth quarter worth $132,000. Finally, Captrust Financial Advisors boosted its stake in Icon by 85.4% during the fourth quarter. Captrust Financial Advisors now owns 1,472 shares of the medical research company’s stock worth $190,000 after buying an additional 678 shares in the last quarter. 85.73% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:ICLR traded down $0.41 during trading on Tuesday, reaching $147.96. The stock had a trading volume of 304,850 shares, compared to its average volume of 291,467. Icon has a 52 week low of $118.10 and a 52 week high of $155.33. The stock has a market capitalization of $7.99 billion, a price-to-earnings ratio of 23.52, a price-to-earnings-growth ratio of 2.03 and a beta of 0.54. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.02 and a quick ratio of 2.02. The firm’s fifty day moving average is $141.77.
Icon (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.63 EPS for the quarter, beating the Zacks’ consensus estimate of $1.60 by $0.03. Icon had a net margin of 12.56% and a return on equity of 25.71%. The company had revenue of $674.85 million for the quarter, compared to analyst estimates of $668.93 million. During the same quarter last year, the firm posted $1.44 earnings per share. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities analysts expect that Icon will post 6.87 earnings per share for the current fiscal year.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Story: Net Asset Value
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.